Answers are grounded in this paper and cite their sources.
Introduction: Thrombosis is an uncommon but clinically important adverse event following vaccination because of its potential for serious morbidity and mortality. Although concerns increased during the coronavirus disease 2019 (COVID-19) vaccination era, comprehensive analyses of thrombosis reports in the Vaccine Adverse Event Reporting System (VAERS) remain limited. Aim: To analyze thrombosis reports submitted to VAERS between 1990 and 2025 and evaluate demographic characteristics, vaccine associations, onset intervals, clinical outcomes, and differences between serious and nonserious reports. Methods: A retrospective observational study was conducted using publicly available VAERS data extracted in May 2026. Reports containing the adverse event term “thrombosis” from 1990 to 2025 were analyzed. Variables included age, sex, vaccine type, onset interval, clinical outcomes, and seriousness classification. Descriptive statistics and Chi-square or Fisher’s exact tests were used. Results: A total of 5565 thrombosis reports were identified, including 2398 (43.1%) serious reports. Females accounted for 59.3% of reports, whereas males were overrepresented in serious cases. Serious outcomes were more common among adults aged ≥65 years. COVID-19 vaccines accounted for the largest proportion of reports. Most documented cases occurred within 1–3 days of vaccination. Hospitalization (33.1%), life-threatening events (17.8%), and death (6.2%) were the most frequent outcomes. Significant differences were observed for age, sex, vaccine type, and onset interval (all P ≤ 0.05). Conclusion: Thrombosis reports showed distinct demographic and clinical patterns, supporting continued postmarketing pharmacovigilance while acknowledging the limitations of passive surveillance in establishing causality.
No takes yet. Share an insight, caveat, or question.
Yalla et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: